UBS analyst AJ Rice lowered the firm’s price target on Ardent Health (ARDT) to $13 from $14 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating
- Underperform Reiterated on Ardent: Aggressive EBITDA Targets and Reimbursement Risks Undermine Valuation
- Ardent Health reports Q4 EPS 32c, consensus 35c
- Ardent Health sees FY26 EPS $0.90-$1.27, consensus $1.35
- Is ARDT a Buy, Before Earnings?